China Resources Pharmaceutical Group Limited (abbreviated as CR Pharma) announced that its wholly-owned subsidiary, China Resources Pharmaceutical Holdings Company Limited, has completed the public issuance of the first tranche of 2026 corporate bonds in mainland China.

The tranche raised RMB1.50 billion with a three-year tenor and an annual coupon rate of 1.65%. The offering forms part of a China Securities Regulatory Commission–approved programme allowing CR Pharmaceutical Holdings to issue up to RMB10 billion in corporate bonds to qualified PRC investors (CSRC approval Zheng Jian Xu Ke [2025] No. 1457).

Net proceeds will be allocated to production expenditures, repayment of corporate debt, replenishment of working capital, project development and operating costs, as well as investments in scientific and technological innovation, in accordance with relevant regulations.

The company reiterated that shareholders and prospective investors should exercise caution when dealing in its securities.